Multiple sclerosis Rx monitor

Summer-2018

The project

• Participants: 76 DMT prescribers
• Geography: 55 regions of Russia
• Most of the data collected during: June-July 2018
• Survey content: doctor opinions + treatment histories

Particular findings

• 86% of DMT patients have their treatments unchanged for at least 12 months
• Half of DMT patients haven’t had aggravations during last 12 months
• Doctors estimate share of 2nd line patients as 13%
• 70% of 2nd line initiations in last 12 months was natalizumab
• 70% of MS prescribers consider clardirbine familiar enough to start Rx (if it was available)

This wave subscription includes:

• Standard report
• Anonymous database of treatment histories’ for in-house analysis
• 607 DMT patients, including 301 treated with 2nd line
• Customized analyses and reporting – to be discussed

Back to the list